Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PRMT5: a putative oncogene and therapeutic target in prostate cancer
Elena Beketova, Jake L. Owens, Andrew M. Asberry, et al.
Cancer Gene Therapy (2021) Vol. 29, Iss. 3-4, pp. 264-276
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Yundong He, Weidong Xu, Yu‐Tian Xiao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 125
Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies
Jiahong Zheng, Bang Li, Yingqi Wu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8407-8427
Closed Access | Times Cited: 39
Overview of the development of protein arginine methyltransferase modulators: Achievements and future directions
Chao Tong, Xiujin Chang, Fangui Qu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116212-116212
Closed Access | Times Cited: 11
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
Yuxuan Che, Yang Liu, Yixin Yao, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 15
BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer
Chi Yin, Min Wang, Yingzhao Wang, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e005532-e005532
Open Access | Times Cited: 15
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
Xuelian Liu, Anjin Wang, Yuying Shi, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1217-1217
Open Access | Times Cited: 13
PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands
Vasudha Mishra, Alka Singh, Michael Korzinkin, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
PRMT5 facilitates angiogenesis and EMT via HIF-1α/VEGFR/Akt signaling axis in lung cancer
Yonghua Zheng, Huaxia Ji, Wulin Yi, et al.
Aging (2023) Vol. 15, Iss. 13, pp. 6163-6178
Open Access | Times Cited: 10
TBL2 Promotes Tumorigenesis via PRMT5/WDR77‐Mediated AKT Activation in Breast Cancer
Xiuqing Lu, Chao Zhang, Lewei Zhu, et al.
Advanced Science (2024)
Open Access | Times Cited: 3
PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen
Samantha L. Tinsley, Brittany L. Allen-Petersen
NAR Cancer (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 14
Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation
Jake L. Owens, Elena Beketova, Sheng Liu, et al.
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 3, pp. 448-459
Open Access | Times Cited: 14
Discovery of tetrahydroisoquinolineindole derivatives as first dual PRMT5 inhibitors/hnRNP E1 upregulators: Design, synthesis and biological evaluation
Wenhui Chu, Na Yang, Jinhe Zhang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115625-115625
Closed Access | Times Cited: 7
PRMT5 mediated FUBP1 methylation accelerates prostate cancer progression
Weiwei Yan, Yang Liu, Xuefeng Qiu, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 18
Open Access | Times Cited: 2
Discovery and Biological Characterization of PRMT5:MEP50 Protein–Protein Interaction Inhibitors
Andrew M. Asberry, Xinpei Cai, Xuehong Deng, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 20, pp. 13793-13812
Closed Access | Times Cited: 11
The cancer testis antigen TDRD1 regulates prostate cancer proliferation by associating with the snRNP biogenesis machinery
Hong Kim, Amrita Barua, Luping Huang, et al.
Oncogene (2023) Vol. 42, Iss. 22, pp. 1821-1831
Closed Access | Times Cited: 6
Exploiting the DNA Damage Response for Prostate Cancer Therapy
Travis H. Stracker, Oloruntoba I. Osagie, Freddy E. Escorcia, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 83-83
Open Access | Times Cited: 6
Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies
Wafaa Abumustafa, Batoul Abi Zamer, Bariaa Khalil, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 145, pp. 112368-112368
Open Access | Times Cited: 14
A New Insight into MYC Action: Control of RNA Polymerase II Methylation and Transcription Termination
Fiorella Scagnoli, Alessandro Palma, Annarita Favia, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 412-412
Open Access | Times Cited: 5
H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets
Liliana Burlibașa, Alina-Teodora Nicu, Mariana Carmen Chifiriuc, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 5
Brg1/PRMT5 nuclear complex epigenetically regulates FOXO1 in IPF mesenchymal progenitor cells
A. Jbeli, Libang Yang, Xia Hong, et al.
AJP Lung Cellular and Molecular Physiology (2024) Vol. 326, Iss. 3, pp. L344-L352
Closed Access | Times Cited: 1
The diel disconnect between cell growth and division inAureococcusis interrupted by giant virus infection
Alexander R. Truchon, Emily E. Chase, Ashton R. Stark, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access | Times Cited: 1
Epigenetic regulation of androgen dependent and independent prostate cancer
Jagdish Mishra, Subhajit Chakraborty, Piyasa Nandi, et al.
Advances in cancer research (2024), pp. 223-320
Closed Access | Times Cited: 1
Medicinal chemistry insights into PRMT5 inhibitors
Zhihao Jiao, Yongmi Huang, Kexin Gong, et al.
Bioorganic Chemistry (2024), pp. 107859-107859
Closed Access | Times Cited: 1
JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer
Jogendra Singh Pawar, Md. Yusuf Al-Amin, Chang‐Deng Hu
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
PRMT5 promotes chemotherapy‐induced neuroendocrine differentiation in NSCLC
Qi Shen, Yi Liu, Xuehong Deng, et al.
Thoracic Cancer (2023) Vol. 14, Iss. 18, pp. 1764-1773
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top